Suchergebnisse - "Sasaki, Koji"

PubPharm (443)

1

Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation : A single-center phase 1,2 trial

enthalten in: American journal of hematology | 2024

von Khouri, I. | Alzahrani, K. | Kantarjian, H. | +20

2

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction : a single-centre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2024

von Bazinet, A. | Kantarjian, H. | Bataller, A. | +17

3

Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy

enthalten in: American journal of hematology | 2024

von Short, N. | Jabbour, E. | Nasr, L. | +10

4

Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression

enthalten in: British journal of haematology | 2024

von Jen, W. | Sasaki, K. | Loghavi, S. | +10

5

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia

enthalten in: Cancer | 2024

von Jabbour, E. | Haddad, F. | Sasaki, K. | +16

6

Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia

enthalten in: Acta haematologica | 2024

von Nasnas, P. | Jabbour, E. | Sasaki, K. | +4

7

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Bazinet, A. | Desikan, S. | Li, Z. | +17

8

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

enthalten in: Leukemia | 2024

von Birdwell, C. | Fiskus, W. | Kadia, T. | +15

9

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia

enthalten in: American journal of hematology | 2024

von Haddad, F. | Sasaki, K. | Issa, G. | +2

10

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

enthalten in: Leukemia | 2024

von Kantarjian, H. | Branford, S. | Breccia, M. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[45]